Close

Celgene (CELG) Receives EC Approval of REVLIMID as Multiple Myeloma Treatment for Ineligible Transplant Patients

February 20, 2015 7:22 AM EST Send to a Friend
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), announced that the European Commission (EC) has approved ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login